Boston University finds blood marker for advanced CTE
A study of 21 former football players linked high protein levels in blood samples to chronic traumatic encephalopathy, offering a potential tool for early diagnosis in living athletes.
By Julian Schulz ·

Researchers at Boston University have identified a blood protein that distinguishes advanced chronic traumatic encephalopathy from healthy brain tissue in a small group of former football players. The study, published in the journal JAMA, analyzed samples from 21 athletes who donated their brains after death. Of those participants, 18 had confirmed CTE, with most showing advanced disease. The team found that players with later-stage CTE had significantly higher concentrations of the protein than those with early-stage disease or no CTE at all.
The protein serves as a marker for tau tangles, which form inside neurons and contribute to brain damage in both CTE and Alzheimer's disease. Co-senior author Michael Alosco, co-director of clinical research at the BU CTE Center, stated that the high concentrations in advanced CTE cases stood out sharply compared to other groups. This distinction allows researchers to differentiate CTE from Alzheimer's, as a second protein associated with Alzheimer's was not linked to CTE in the analysis.
Alosco described the work as a step toward diagnosing the disease in living people, a goal that has eluded medical experts for decades. Since CTE can currently only be confirmed through brain tissue analysis after death, the condition's true prevalence and progression among living individuals remain difficult to measure. This lack of diagnostic clarity has complicated the development of prevention strategies and treatments for athletes and military personnel who suffer repeated head impacts.
The potential impact of CTE on football players has drawn attention recently. A study published in October estimated that nearly three-quarters of all NFL players who died during a recent 15-year period had the condition. While the disease is most associated with contact sports, it has also been found in the brains of individuals in the military. Symptoms often include cognitive impairment, dementia, and severe mood or behavior changes, though not every person with CTE develops noticeable signs, particularly in the early stages.
Experts caution that the findings are preliminary. Dr. Ramon Diaz-Arrastia, a neurology professor at the University of Pennsylvania, noted that the sample size was too small to establish diagnostic thresholds. Derek Monroe, an assistant professor at UNC Chapel Hill, pointed out that the participants did not represent the wider population or all football players, as the group included few people with early-stage disease or no disease. He suggested that future diagnosis will likely require a combination of blood tests and brain imaging.
The BU researchers collaborated with colleagues at Banner Health in Arizona to conduct the analysis. They noted that a separate study by scientists at Washington University in St. Louis found similar results using a different method. Chihiro Sato, an assistant professor of neurology at Washington University, called it encouraging that two independent groups reached the same conclusion. Alosco said that more people are now participating in studies and donating brains, positioning researchers to validate these findings in larger samples in the near future.
Richard McElroy, a former collegiate football player from Mississippi State, was one of the participants. His family said his behavior changed in his early 50s, including sudden angry outbursts and heavy drinking. After his death in January at age 74, his brain was analyzed and he was diagnosed with stage 4 CTE. His daughter, Kristina McElroy, said his participation allows him to help other people. The family expressed a wish that he could have been diagnosed sooner, but welcomed the chance for his brain to contribute to medical science.
The study represents a specific advance in identifying biomarkers for head trauma-related brain disease. While no approved blood test for CTE exists yet, the results provide a concrete target for further clinical research. The findings suggest that blood tests may eventually help monitor the progression of the disease in living patients, potentially leading to earlier interventions for those at risk.






